



28 July 2015

Resonance Health Ltd (ASX:RHT) Appendix 4C – 4th Quarter Cash Flow Report

Resonance Health Limited today released its 4th quarter Cash Flow Report for the period ending 30 June 2015.

Cash at 30 June 2015 was \$2.797million.

Receipts from customers for the June quarter was \$582,000.

During this quarter the Company signed a two-year agreement with a pharmaceutical company for the provision of FerriScan and cardiac T2* services in a phase II multi-centre study. The study has a target commencement date of late 2015.

The marketing spend in the June quarter, as planned, was \$153,000. Company delegates headed to the USA, China, Austria, United Kingdom, and Italy to participate in carefully selected conferences and meet with key stakeholders. These profiling activities increased awareness of HepaFat-Scan® and FerriScan® in the global clinical community and generated further opportunities. Marketing efforts are being increased and the Company has appointed additional marketing resources in the USA and Germany. Conference attendance in the coming quarter will include:

- Australia New Zealand Hepatic, Pancreatic and Biliary Association (Annual Meeting)
- Sickle Cell Disease Association of America (Annual Convention)
- Thalassaemia International Federation Pan-Asian Conference on Haemoglobinopathies

Resonance Health commenced a HepaFat-Scan validation study at Children's Healthcare of Atlanta in a paediatric patient population. The first patient scans were received this month and total recruitment is expected to take 12 months.

Research and development spend was in line with our planned budget of \$127,000 focused on the development of a non-invasive liver fibrosis measurement technology.

An abstract was submitted to the American Association for the Study of Liver Disease (AASLD) with promising results from a prototype liver fibrosis measurement technology that distinguishes between low and high fibrosis scores in a Hepatitis C patient cohort. The Company is working on obtaining additional test data to validate the technology. At the same time the Company continues to explore other avenues to develop its fibrosis technology and as part of this strategy has commenced a collaboration with CSIRO. Other R&D projects to develop prototype quantitative methods to measure liver fibrosis are anticipated to commence in the second half of this year.

Investors can subscribe to our ASX market releases via our web site.
<http://www.resonancehealth.com/investors/asx-subscribe.html>

For further information please contact:

Resonance Health

Adrian Bowers

Company Secretary

T: +61 8 9286 5300

E: adrianb@resonancehealth.com

+ See chapter 19 for defined terms.

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

30 June 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date \$A'000
1.1 Receipts from customers	582	2,489
1.2 Payments for		
(a) staff costs	(265)	(1,397)
(b) advertising and marketing	(153)	(407)
(c) research and development	(127)	(297)
(d) leased assets	-	-
(e) other working capital	(57)	(278)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	13	70
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/received	-	-
1.7 Other Receipts/Payments		
(a) consulting & professional services	(50)	(78)
(b) statutory & compliance	(58)	(182)
(c) grants	27	162
(d) Due diligence expense	-	(43)
Net operating cash flows	(88)	39

Appendix 4C
Quarterly report for entities
admitted on the basis of commitment

		Current quarter	Year to date
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)		
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(7)	(11)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (Cash introduced on acquisition of controlled entity)	-	-
	Net investing cash flows	(7)	(11)
1.14	Total operating and investing cash flows	(95)	28
Cash flows related to financing activities			
1.15	Proceeds from issues of shares, options, etc.	-	650
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (costs of capital raising)	-	(19)
	Net financing cash flows	-	631
	Net increase (decrease) in cash held	(95)	659
1.21	Cash at beginning of quarter/year to date	2,892	2,097
1.22	Exchange rate adjustments to item 1.20	-	41
1.23	Cash at end of quarter	2,797	2,797

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	\$32k
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	\$32K – Directors fees	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A.

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	557	665
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details) - Term deposits	2,240	2,227
Total: cash at end of quarter (item 1.22)	2,797	2,892

Acquisitions and disposals of business entities

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Adrian Bowers
Company Secretary